Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation

ESMO Open. 2019 May 21;4(3):e000515. doi: 10.1136/esmoopen-2019-000515. eCollection 2019.

Authors

Mariana Brandão¹, Fabien Reyal^{2

3}, Anne-Sophie Hamy³, Martine Piccart-Gebhart¹

Affiliations

¹ Université Libre de Bruxelles, Institut Jules Bordet, Bruxelles, Belgium.
² Residual Tumor & Response to Treatment Laboratory, PSL Research University, Paris, France.
³ Breast and Gynecologic Cancer and Reconstructive Surgery Team, Institut Curie, Paris, France.

No abstract available

Keywords: breast cancer; neoadjuvant treatment; treatment.

Publication types

Editorial